Effective oral hypomethylating drugs in intermediate-risk or high-risk myelodysplasia: a breakthrough?

Lancet Haematol. 2019 Apr;6(4):e170-e171. doi: 10.1016/S2352-3026(19)30025-0.
No abstract available

MeSH terms

  • Administration, Oral
  • Azacitidine / administration & dosage*
  • Azacitidine / pharmacology*
  • Azacitidine / therapeutic use
  • DNA Methylation / drug effects*
  • Decitabine / administration & dosage*
  • Decitabine / pharmacology*
  • Decitabine / therapeutic use
  • Humans
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / genetics*
  • Risk

Substances

  • Decitabine
  • Azacitidine